Introduction {#s1}
============

Respiratory inflammation has a central role in the pathophysiology of COPD. Inhaled corticosteroids (ICS) are the principal anti-inflammatory treatment for COPD (Global initiative for chronic obstructive lung disease (GOLD), [@B18]), but little is known about the pattern of inflammatory markers which are affected by this pharmacotherapy. While ICS are generally effective in asthma, their anti-inflammatory efficacy in COPD is not clearly established (Barnes, [@B3]).

Electronic noses (e-noses), consisting of cross-reactive chemical sensor arrays for the detection of volatile chemical species (Horvath et al., [@B21]), discriminate between patients with COPD, asthmatic patients, healthy smokers and healthy non-smokers (Fens et al., [@B17]), and predict oral corticosteroid responsiveness in asthmatic patients (van der Schee et al., [@B35]). E-nose breathprints are associated with airway inflammatory markers, including sputum eosinophils and neutrophils, in COPD patients and can be useful for subphenotyping (Fens et al., [@B15], [@B16]). Metabolomics is a global approach to understanding regulation of metabolic pathways and metabolic networks of a biological system (Rochfort, [@B32]). Nuclear magnetic resonance (NMR)-based metabolomic analysis of exhaled breath condensate (EBC), the liquid fraction of exhaled breath, is suitable for identifying and quantifying semi-volatile/non-volatile small molecular weight metabolites and has been applied to the assessment of airway inflammation in COPD patients (De Laurentiis et al., [@B9]; Motta et al., [@B28]; Airoldi et al., [@B1]). Published prospective clinical studies on effects of pharmacological treatment on breathomics in COPD patients are not available.

We aimed to assess the effects of treatment and steroid withdrawal of an extrafine ICS/long-acting β~2~-agonist (LABA) fixed dose combination (FDC) on breathprints and non-invasive inflammatory outcomes in COPD patients; to compare accuracy of a multidimensional classification model vs. a standard spirometry-based model.

Methods {#s2}
=======

Study subjects
--------------

Fourteen COPD ex-smokers for at least 1 year with stable mild, moderate or severe airflow limitation (GOLD stage I-III, post-bronchodilator forced expiratory volume in 1 s (FEV~1~) \>30% predicted value, FEV~1~/FVC \< 70%, GOLD group A-D), who were on a fixed dose combination (FDC) of fluticasone propionate/salmeterol delivered via a dry powder inhaler (DPI) at a constant dose of 500/50 μg b.i.d. for at least 8 weeks, were studied. Diagnosis of COPD was based on GOLD guideline criteria (Global initiative for chronic obstructive lung disease (GOLD), [@B18]). Six subjects had clinical and radiological signs of emphysema. Three patients had bronchiectasis documented by chest CT scan. Regarding co-morbidities, six patients with COPD had concomitant ischemic heart disease, four patients had congestive heart failure, five patients had arterial blood hypertension, three patients had type 2 diabetes mellitus, and one patient had peripheral vascular disease.

COPD patients had negative reversibility test to 400 μg of inhaled salbutamol (\< 12% and 200 ml increase in FEV~1~), no history of asthma and atopic disease, negative skin prick test results, no upper respiratory tract infections in the previous 3 weeks, and were excluded from the study if they had used systemic corticosteroids in the previous 4 weeks.

Study design
------------

This was a single center, prospective, open label, pilot, proof-of-concept, pharmacological study of ICS withdrawal and treatment in COPD patients on maintenance treatment with inhaled fluticasone propionate/salmeterol at full doses (visit 1, screening visit). Study duration was 10 weeks including 4 visits (Figure [1](#F1){ref-type="fig"}). After a 2-week phase treatment with inhaled beclomethasone/formoterol (100/6 μg 2 puffs b.i.d. via pressurized metered dose inhaler \[pMDI\]) (visit 2, baseline visit) to allow them to become familiar with the new inhaler, patients received inhaled formoterol alone (6 μg 2 puffs b.i.d. via pMDI) for 4 weeks (visit 3, post-withdrawal visit), and inhaled beclomethasone/formoterol (100/6 μg 2 puffs b.i.d.) for 4 weeks (visit 4, post-treatment visit) (Figure [1](#F1){ref-type="fig"}). Breathomics included analysis of exhaled breath gaseous phase with two different e-noses, and NMR-based metabolomics of exhaled breath condensate (EBC). Sputum cell counts, prostaglandin (PG) E~2~ and 15-F~2t~-isoprostane in sputum supernatants and EBC, and fraction of exhaled nitric oxide (F~E~NO) were also measured.

![Study design and detail of interventions. At screening visit (visit 1), treatment with a constant dose of inhaled fluticasone propionate/salmeterol xinafoate fixed dose combination (FDC) (500/50 μg b.i.d. via a dry powder inhaler) for at least 8 weeks was switched to an extrafine formulation of inhaled beclomethasone dipropionate (BDP)/formoterol fumarate (FOR) FDC (100/6 μg 2 puffs b.i.d. via a pressurized metered dose inhaler \[pMDI\]). After a run-in phase of 2 weeks, the FDC containing beclomethasone was suspended (visit 2, baseline visit), while maintaining formoterol alone (6 μg 2 puffs b.i.d. via pMDI). After 4 weeks of beclomethasone withdrawal (visit 3, post-withdrawal visit), treatment with inhaled beclomethasone/formoterol FDC at the same dose (100/6 μg 2 puffs b.i.d. via pMDI) was reintroduced. Exhaled breath sampling for e-nose analysis, measurement of fraction of exhaled nitric oxide (F~E~NO), exhaled breath condensate (EBC) collection, pulmonary function tests (PFT), and sputum induction were performed at each visit. Study duration was 10 weeks.](fphar-09-00258-g0001){#F1}

Both informed and written consent was obtained from patients. The study was approved by the Ethics Committee (A.942/C.E./2012) of the Catholic University of the Sacred Heart, University Hospital Agostino Gemelli, Rome, Italy. EudraCT number: 2012-001749-42.

Pulmonary function
------------------

Spirometry was performed with a Pony FX spirometer (Cosmed, Rome, Italy) and the best of three consecutive maneuvers chosen.

F~E~NO measurement
------------------

F~E~NO was measured with the NIOX system (Aerocrine, Stockholm, Sweden) with a single breath on-line method at constant flow of 50 ml/sec according to American Thoracic Society guidelines (American Thoracic Society and European Respiratory Society, [@B2]; Dweik et al., [@B12]). Exhalations were repeated after 1 min relaxation period until the performance of three F~E~NO values varies less than 10% (American Thoracic Society and European Respiratory Society, [@B2]). F~E~NO measurements were obtained before spirometry.

Collection of exhaled breath
----------------------------

Exhaled breath was collected from each subject at 8.30 a.m. as previously described (Fens et al., [@B17]; Bofan et al., [@B7]) and based on recent ERS technical standard (Horvath et al., [@B21]). No food or drinks were allowed at least 12 h prior to sampling.

Subjects were asked to breathe tidally volatile organic compound (VOC)-filtered air for 5 min, while wearing a nose-clip, into a 2-way non-rebreathing valve with an inspiratory VOC filter and an expiratory silica reservoir to reduce sample water vapor (Röck et al., [@B33]). Then, subjects were asked to inhale to maximal inspiration and perform a FVC maneuver into a Tedlar® bag. Two consecutive samples were collected 15 min apart and immediately analyzed.

Electronic noses
----------------

The first sample was analyzed with a commercially available e-nose (Cyranose 320, Sensigent, Baldwin Park, USA) (Lewis, [@B22]; Fens et al., [@B17]) which consists of an array of 32 cross-reactive carbon black polymer composite sensors and detects resistance variations; the second sample was analyzed with an e-nose prototype (Ten 2011, University of Rome Tor Vergata, Italy) (Montuschi et al., [@B27]) which consists of an array of 8 cross-reactive quartz microbalance gas sensors coated by molecular films of metallo-porphyrins and detects frequency variations (Montuschi et al., [@B27]). Breathprints were analyzed by pattern recognition algorithms (Bishop, [@B6]).

Ambient VOCs were subtracted from measures and results were automatically adjusted for ambient VOCs.

EBC sampling
------------

Before EBC collection, subjects refrained from eating for at least 3 h. EBC was collected using a condenser (Ecoscreen, Jaeger, Hoechberg, Germany) (Motta et al., [@B28]), in a windowless clinic facility without disinfectant dispensers (Motta et al., [@B28]). Samples were snap frozen in liquid nitrogen to immediately "quench" metabolism and preserve the metabolite concentrations.

Metabolomic analysis of EBC with NMR spectroscopy
-------------------------------------------------

^1^H-NMR spectra for EBC samples were acquired using a Bruker 600 MHz spectrometer operating at 600.13 MHz using standard nuclear Overhauser effect spectroscopy (NOESY) experiments and standard protocols for sample preparation (Bertini et al., [@B4]). Signals of interest were assigned on template one-dimensional NMR profiles and integrated to calculate their relative concentrations (Montuschi et al., [@B25]; Motta et al., [@B28]; Bertini et al., [@B4]). Multilevel partial least squares (PLS) analysis was used to analyse EBC spectra from the same subject obtained at paired visits.

Measurement of PGE~2~ and 15-F~2t~-isoprostane in sputum supernatants and EBC
-----------------------------------------------------------------------------

PGE~2~ and 15-F~2t~-isoprostane concentrations in sputum supernatants and EBC were measured with radioimmunoassays developed in our laboratory, previously validated and compared with gas chromatography/mass spectrometry and high performance liquid chromatography (Wang et al., [@B37]; Montuschi et al., [@B26]).

Sputum cell analysis
--------------------

Sputum induction, processing and analysis were performed according to the European Respiratory Society (ERS) guidelines (Djukanovic et al., [@B11]; Efthimiadis et al., [@B14]; Paggiaro et al., [@B29]).

Baseline FEV~1~ was recorded before sputum induction. Subjects were pre-treated with inhaled salbutamol (400 μg), and, after 10 min, a spirometry was repeated (Paggiaro et al., [@B29]). Subjects were asked to inhale hypertonic saline (3%) for 5 min and then, to rinse their mouths and try to expectorate into a sterilized box (Paggiaro et al., [@B29]). Five-minute inhalation sessions were repeated four times for a total of 20 min (Paggiaro et al., [@B29]). A spirometry was performed after each inhalation session to detect significant fall of FEV~1~. The procedure was stopped when approximately 1 g of plugs was collected, or if patients had symptoms or/and if FEV~1~ was reduced more than 20% over baseline values (Paggiaro et al., [@B29]). Sputum was processed within 2 h to ensure optimum cell counting and staining, with the sample always kept in ice (Efthimiadis et al., [@B14]). One hundred to 500 μg sputum was selected for sputum analysis. Dithiothreitol (DTT) 0.1% was added to sputum samples which were kept in a shaking rocker at room temperature for 20 min for sample homogenization (Efthimiadis et al., [@B14]). Samples were filtered through a 48 μm nylon mesh into a pre-weighed conical tube and filtrate was weighed. Total cell count was performed manually using a haemocytometer and cell viability was assessed by the trypan blue exclusion method before centrifugation (Efthimiadis et al., [@B14]). To separate cell pellet from sputum supernatants, samples were centrifuged at 4°C for 10 min with a centrifugal force of 1,200 × g (Efthimiadis et al., [@B14]). Sputum supernatant samples were collected and stored at −80°C for measurement of PGE~2~ and 15-F~2t~-isoprostane concentrations. Cell pellets were resuspended in PBS buffer and cell concentrations were adjusted to 1 × 10^6^ cells/ml. Cytospins were prepared by adding 40--60 μl of cell resuspension to each cytospin and using a Shandon cytocentrifuge at 22 × g for 6 min (Efthimiadis et al., [@B14]). Cytospins were stained for differential cell counts using Giemsa staining (Efthimiadis et al., [@B14]). The differential cell counts were performed by counting a minimum of 400 nonsquamous cells and reported as the relative numbers of eosinophils, neutrophils, macrophages, lymphocytes, and bronchial epithelial cells, expressed as a percentage of total non-squamous cells (Efthimiadis et al., [@B14]). The percentage of squamous cells was reported separately. Slides with squamous cells \>30% of total cells were discarded. Slides were read blindly by two qualified and fully trained physicians. Monthly quality control was performed including internal slide reading and equipment calibration.

Skin testing
------------

Atopy was assessed by skin prick tests for common aeroallergens (mixture for house dust mite \[Dermatophagoides pteronyssinus and Dermatophagoides farinae, grass pollen \[cocksfoot and timothy\], weed pollen \[Parietaria officinalis and Ambrosia artemisifolia\], tree pollen \[birch, ash tree, olive tree, oak, and cypress\], animal danders \[cat and dog allergens\], and fungal allergens \[Aspergillus species and Alternaria alternata\]; (Stallergenes, Antony, France) (Montuschi et al., [@B24]). A positive skin test response was defined as a wheal with a mean diameter (mean of maximum and 90° midpoint diameters) of at least 3 mm greater than that produced with a saline control (Montuschi et al., [@B24]).

Multivariate data analysis
--------------------------

E-nose and NMR spectroscopy data analysis requires multivariate statistical algorithms (Bishop, [@B6]; Wilson and Baietto, [@B40]). Multilevel PLS was used for data reduction; the K-nearest neighbors method, applied on the multilevel PLS scores, was used for classification purposes (Bishop, [@B6]; Wilson and Baietto, [@B40]). The global classification accuracy was assessed by means of Monte Carlo cross-validation scheme. The threshold for significant classification was set at a value of 70% (Bijlsma et al., [@B5]). Correlations among multidimensional data were calculated using the algorithm implemented in the R-library "psych" (Hahsler et al., [@B19]; Revelle, [@B31]) and are shown as a heatmap built using the R-function "heatmap.2," implemented in the "gplots" package (Warnes et al., [@B38]).

Statistical analysis
--------------------

Data were expressed as mean ± SEM or medians and interquartile ranges (25^th^ and 75^th^ percentiles), after assessing for normality with the D\'Agostino-Pearson omnibus normality test. Depending on data distribution, repeated-measures ANOVA or Friedman test was used for assessing within-group pharmacological treatment effect. If overall P value was found significant, paired *t*-test or Wilcoxon signed rank test were performed. Correlation was expressed as a Pearson coefficient. Significance was defined as a value of *P* \< 0.05.

In this pilot, proof-of-concept study, we did not adjust our analysis for multiple testing to reduce the risk of missing promising biomarkers, but this also increased our risk of a type I error. Further details on the methodology are provided in the online Supplementary Material (Presentation [1](#SM6){ref-type="supplementary-material"}).

Results {#s3}
=======

Study subjects
--------------

Subject characteristics are shown in Table [1](#T1){ref-type="table"}.

###### 

Subject characteristics[^\*^](#TN1){ref-type="table-fn"}.

                                                                        **COPD patients (*n* = 14)**
  --------------------------------------------------------------------- ------------------------------
  Age, years                                                            73.6 ± 1.8
  Gender, females/males                                                 2/14
  Pack-years                                                            64.3 ± 8.1
  GOLD I/II/III, airflow limitation severity                            5/5/4
  GOLD A/B/C/D classification                                           1/7/3/3
  [^§^](#TN2){ref-type="table-fn"}Skin prick tests, positive/negative   0/14
  History of atopy, positive/negative                                   0/14
  [^\#^](#TN3){ref-type="table-fn"}Sputum eosinophils ≥ 3% at visit 1   0/14

*Data are expressed as numbers or mean ± SEM*.

*Common aeroallergens were tested*.

*Expressed as percentage of total non-squamous cells*.

Pulmonary function testing
--------------------------

Pre-bronchodilator and post-bronchodilator lung function test values across visits in patients with COPD are shown in Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, respectively. Higher mean pre-bronchodilator forced expiratory flow at 25--75% of forced vital capacity (FEF~25−75%~) percentage of predicted and absolute values were observed after 2-week inhaled beclomethasone/formoterol FDC (visit 2) compared with post-4-week treatment with inhaled formoterol alone (visit 3) (*P* = 0.026 and *P* = 0.029, respectively) (Figures [2A,B](#F2){ref-type="fig"}; Table [2](#T2){ref-type="table"}).

###### 

Lung function tests, pre-bronchodilator values[^\*^](#TN4){ref-type="table-fn"}.

                             **Visit 1 Screening (*n* = 14)**              **Visit 2 Baseline (*n* = 14)**               **Visit 3 Post-withdrawal (*n* = 14)**        **Visit 4 Post-treatment (*n* = 14)**   ***P* value**
  -------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------- ---------------
  FEV~1~, L                  1.66 ± 0.21                                   1.68 ± 0.22                                   1.65 ± 0.21                                   1.67 ± 0.21                             0.907
  FEV~1~, % predicted        61.8 ± 6.9                                    62.7 ± 7.0                                    61.9 ± 6.7                                    62.4 ± 6.5                              0.962
  FVC, L                     2.80 ± 0.28                                   2.86 ± 0.28                                   2.92 ± 0.28                                   2.91 ± 0.28                             0.440
  FVC, % predicted           79.9 ± 6.3                                    81.8 ± 5.9                                    84.0 ± 6.0                                    83.3 ± 5.5                              0.534
  FEV~1~/FVC, %              58.1 ± 3.2[^1^](#TN5){ref-type="table-fn"}    57.2 ± 3.1                                    55.3 ± 3.2[^1^](#TN5){ref-type="table-fn"}    56.3 ± 3.3                              0.008
  PEF, L/s                   4.81 ± 0.65[^2^](#TN6){ref-type="table-fn"}   5.24 ± 0.72[^2^](#TN6){ref-type="table-fn"}   4.89 ± 0.70                                   4.93 ± 0.62                             0.044
  PEF, % predicted           65.5 ± 8.1[^2^](#TN6){ref-type="table-fn"}    71.3 ± 8.9[^2^](#TN6){ref-type="table-fn"}    66.8 ± 8.8                                    67.2 ± 7.4                              0.033
  FEF~25−75%~, L/s           0.92 ± 0.14                                   0.94 ± 0.15[^3^](#TN7){ref-type="table-fn"}   0.86 ± 0.13[^3^](#TN7){ref-type="table-fn"}   0.92 ± 0.14                             0.029
  FEF~25−75%~, % predicted   32.4 ± 4.6                                    32.9 ± 4.9[^3^](#TN7){ref-type="table-fn"}    30.2 ± 4.2[^3^](#TN7){ref-type="table-fn"}    32.6 ± 5.4                              0.026

*Data are expressed as numbers or mean ± SEM. Within-group comparisons were performed with ANOVA for repeated measures and paired t-test. P \< 0.05 was considered significant*.

V1 vs. V3;

V1 vs. V2;

*V2 vs. V3*.

*Abbreviations: FEF~25−75%~, forced expiratory flow at 25--75% of the forced vital capacity; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow*.

###### 

Lung function tests, post-bronchodilator values[^\*^](#TN8){ref-type="table-fn"}.

                             **Visit 1 (*n* = 14)**   **Visit 2 (*n* = 14)**   **Visit 3 (*n* = 14)**   **Visit 4 (*n* = 14)**   ***P*-Value**
  -------------------------- ------------------------ ------------------------ ------------------------ ------------------------ ---------------
  FEV~1~, L                  1.77 ± 0.22              1.80 ± 0.22              1.79 ± 0.22              1.79 ± 0.22              0.902
  FEV~1~, % predicted        66.2 ± 7.0               67.6 ± 7.2               67.0 ± 7.0               66.4 ± 7.0               0.854
  FVC, L                     2.98 ± 0.28              3.01 ± 0.28              3.07 ± 0.26              3.06 ± 0.28              0.547
  FVC, % predicted           85.3 ± 6.2               86.4 ± 6.0               88.7 ± 5.9               87.5 ± 5.6               0.587
  FEV~1~/FVC, %              58.3 ± 3.3               58.5 ± 3.3               56.5 ± 3.1               56.7 ± 3.3               0.110
  PEF, L/sec                 5.38 ± 0.72              5.29 ± 0.64              5.19 ± 0.70              5.12 ± 0.71              0.427
  PEF, % predicted           73.1 ± 8.9               72.4 ± 7.9               70.9 ± 8.70              69.4 ± 8.50              0.437
  FEF~25−75%~, L/sec         0.99 ± 0.15              1.03 ± 0.16              0.96 ± 0.15              0.96 ± 0.16              0.447
  FEF~25−75%~, % predicted   34.7 ± 4.8               36.3 ± 5.2               33.7 ± 4.9               34.0 ± 5.5               0.493

*Data are expressed as numbers or mean ± SEM. Within-group comparisons were performed with ANOVA for repeated measures and paired t-test. P \< 0.05 was considered significant*.

*FEF~25−75%~, forced expiratory flow at 25--75% of the forced vital capacity; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow*.

![Pre-bronchodilator forced expiratory flow at the 25-75% of the forced vital capacity (FEF~25−75%~) and peak expiratory flow (PEF) values in 14 patients with COPD at visit 1 (V1) to visit 4 (V4). **(A)** FEF~25−75%~ percentage predicted values; **(B)** absolute FEF~25−75%~ values; **(C)** PEF percentage predicted values; **(D)** absolute PEF values. Mean values ± SEM are shown.](fphar-09-00258-g0002){#F2}

Mean pre-bronchodilator FEV~1~/FVC ratio was higher on maintenance treatment with fluticasone propionate/salmeterol FDC (visit 1) compared with post-treatment with formoterol alone (visit 3) (*P* = 0.008) (Table [2](#T2){ref-type="table"}).

Higher mean pre-bronchodilator peak expiratory flow (PEF) percentage of predicted and absolute values were observed after 2-week beclomethasone/formoterol FDC (visit 2) compared with maintenance treatment with inhaled fluticasone propionate/salmeterol (visit 1) (*P* = 0.033 and *P* = 0.044, respectively) (Figures [2C,D](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). No within-group differences in post-bronchodilator functional parameters were observed (Table [3](#T3){ref-type="table"}).

Electronic nose
---------------

E-nose analysis with either e-nose was successfully performed in all 14 subjects at all visits. A total of 56 breathprints for each e-nose was collected. Fifteen out of 32 carbon polymer sensors showed significant mean differences between inhaled fluticasone propionate/salmeterol FDC maintenance treatment (visit 1) and post-4-week beclomethasone/formoterol FDC treatment (visit 4), whereas 7 sensors showed significant mean differences between fluticasone propionate/salmeterol maintenance treatment (visit 1) and 2-week treatment with beclomethasone/formoterol (visit 2) (Table [4](#T4){ref-type="table"}).

###### 

Univariate analysis of carbon polymer sensor e-nose response[^\*^](#TN9){ref-type="table-fn"}.

  **V1**               **V2**               **V3**               **V4**               ***P*-value**
  -------------------- -------------------- -------------------- -------------------- ---------------
  **Sensor 1**                                                                        
  2.507 ± 0.2171       2.843 ± 0.1636       2.891 ± 0.2411       3.208 ± 0.1857       0.0480
  V1 vs. V4                                                                           0.0055
  **Sensor 2**                                                                        
  1.664 ± 0.1427       1.891 ± 0.0979       1.934 ± 0.1537       2.181 ± 0.1260       0.0212
  V1 vs. V2                                                                           0.0364
  V1 vs. V4                                                                           0.0053
  Sensor 3                                                                            
  2.527 ± 0.2057       2.768 ± 0.1549       2.868 ± 0.2432       3.183 ± 0.1993       n.s.
  **Sensor 4**                                                                        
  1.447 ± 0.1191       1.640 ± 0.0891       1.693 ± 0.1378       1.926 ± 0.1249       0.0209
  V1 vs. V4                                                                           0.0040
  Sensor 5                                                                            
  11.27 ± 1.195        12.86 ± 0.8729       13.38 ± 1.261        16.70 ± 2.785        n.s.
  Sensor 6                                                                            
  6.574 ± 0.7314       7.547 ± 0.5477       7.757 ± 0.8441       8.510 ± 0.6821       n.s.
  **Sensor 7**                                                                        
  0.001109 ± 0.0962    0.001253 ± 0.0678    0.001265 ± 0.1008    0.001409 ± 0.0763    0.0409
  V1 vs. V4                                                                           0.0053
  **Sensor 8**                                                                        
  0.6803 ± 0.05038     0.7709 ± 0.03499     0.7732 ± 0.05597     0.8569 ± 0.05064     0.0259
  V1 vs. V2                                                                           0.0216
  V1 vs. V4                                                                           0.0058
  Sensor 9                                                                            
  2.154 ± 0.2058       2.462 ± 0.1496       2.542 ± 0.2280       2.811 ± 0.1892       n.s.
  Sensor 10                                                                           
  1.283 ± 0.1128       1.474 ± 0.08070      1.492 ± 0.1259       1.649 ± 0.1020       n.s.
  Sensor 11                                                                           
  1.277 ± 0.1155       1.429 ± 0.0759       1.460 ± 0.1267       1.607 ± 0.0973       n.s.
  **Sensor 12**                                                                       
  1.321 ± 0.1193       1.487 ± 0.0781       1.559 ± 0.1282       1.715 ± 0.0970       0.0300
  V1 vs. V4                                                                           0.0046
  Sensor 13                                                                           
  1.036 ± 0.0877       1.185 ± 0.0624       1.196 ± 0.0981       1.315 ± 0.0757       n.s.
  **Sensor 14**                                                                       
  0.8994 ± 0.0752      1.014 ± 0.0542       1.048 ± 0.0820       1.163 ± 0.0604       0.0258
  V1 vs. V4                                                                           0.0051
  **Sensor 15**                                                                       
  2.225 ± 0.1933       2.513 ± 0.1338       2.577 ± 0.2234       2.881 ± 0.1799       0.045
  V1 vs. V4                                                                           0.0071
  **Sensor 16**                                                                       
  1.241 ± 0.1085       1.405 ± 0.0809       1.447 ± 0.1203       1.577 ± 0.0962       0.0100
  V1 vs. V4                                                                           0.0094
  Sensor 17                                                                           
  1.430 ± 0.1237       1.603 ± 0.0880       1.637 ± 0.1437       1.804 ± 0.1222       n.s.
  Sensor 18                                                                           
  2.643 ± 0.2480       3.000 ± 0.1781       3.093 ± 0.2729       3.385 ± 0.2228       n.s.
  **Sensor 19**                                                                       
  0.9070 ± 0.0727      1.033 ± 0.0569       1.075 ± 0.0908       1.172 ± 0.0648       0.0273
  V1 vs. V2                                                                           0.0320
  V1 vs. V4                                                                           0.0052
  Sensor 20                                                                           
  2.341 ± 0.2267       2.658 ± 0.1648       2.702 ± 0.2400       2.910 ± 0.1990       n.s.
  **Sensor 21**                                                                       
  0.8288 ± 0.0683      0.9423 ± 0.0510      0.9509 ± 0.0762      1.057 ± 0.0597       0.0362
  V1 vs. V2                                                                           0.0307
  V1 vs. V4                                                                           0.0062
  Sensor 22                                                                           
  1.004 ± 0.0863       1.132 ± 0.0594       1.132 ± 0.0935       1.233 ± 0.0767       n.s.
  Sensor 23                                                                           
  9.586 ± 0.9759       10.94 ± 0.7091       11.47 ± 1.157        13.26 ± 1.443        n.s.
  **Sensor 24**                                                                       
  1.403 ± 0.1185       1.597 ± 0.0943       1.704 ± 0.1439       1.904 ± 0.0872       0.0084
  V1 vs. V2                                                                           0.0404
  V1 vs. V4                                                                           0.0030
  V2 vs. V4                                                                           0.0365
  **Sensor 25**                                                                       
  1.426 ± 0.1198       1.618 ± 0.0865       1.635 ± 0.1300       1.849 ± 0.1003       0.0286
  V1 vs. V2                                                                           0.0494
  V1 vs. V4                                                                           0.0051
  Sensor 26                                                                           
  0.003672 ± 0.3577    0.004201 ± 0.2878    0.004370 ± 0.4194    0.004926 ± 0.4143    n.s.
  **Sensor 27**                                                                       
  0.0005989 ± 0.0456   0.0006938 ± 0.0359   0.0007088 ± 0.0597   0.0007838 ± 0.0412   0.0182
  V1 vs. V2                                                                           0.0170
  V1 vs. V4                                                                           0.0013
  Sensor 28                                                                           
  0.004238 ± 0.4047    0.004810 ± 0.2025    0.004937 ± 0.4320    0.005434 ± 0.3809    n.s.
  Sensor 29                                                                           
  2.228 ± 0.2167       2.521 ± 0.1581       2.573 ± 0.2285       2.890 ± 0.2030       n.s.
  Sensor 30                                                                           
  0.9987 ± 0.0863      1.151 ± 0.0666       1.170 ± 0.0987       1.301 ± 0.0946       n.s.
  Sensor 31                                                                           
  15.13 ± 1.761        17.41 ± 1.240        18.35 ± 2.133        24.58 ± 6.076        n.s.
  **Sensor 32**                                                                       
  0.6599 ± 0.0538      0.7333 ± 0.0397      0.7486 ± 0.0599      0.8363 ± 0.0437      0.0426
  V1 vs. V4                                                                           0.0066

*The behavior of each sensor (sensor 1--sensor 32) is shown. Sensors whose mean values differ across visits are shown in bold*.

*Data, expressed as mean ± SEM, are relative changes in sensor resistance \[(Rmax-R0)/R0\] (μOhms). Intra-group, between-visit comparisons were performed with ANOVA for repeated measures. If overall P was lower than 0.05, considered significant, paired t-test was performed. n.s., not significant; V, visit*.

Consistent with carbon polymer sensor behavior, two quartz crystal sensors showed significant mean differences between fluticasone propionate/salmeterol maintenance treatment (visit 1) and post-4-week beclomethasone/formoterol FDC treatment (visit 4); sensor 3 and 4 showed significant mean differences between fluticasone propionate/salmeterol maintenance treatment (visit 1) and 2-week beclomethasone/formoterol treatment (visit 2) (Table [5](#T5){ref-type="table"}).

###### 

Univariate analysis of quartz crystal sensor e-nose response[^\*^](#TN10){ref-type="table-fn"}.

  **V1**              **V2**                **V3**                **V4**                ***P***
  ------------------- --------------------- --------------------- --------------------- ---------
  Sensor 1                                                                              
  21.5 (14.75--31)    30 (19--38)           27.5 (21.75--36.75)   30.5 (22.75--38.25)   n.s.
  **Sensor 2**                                                                          
  19 (14--29)         27.5 (20.5--32.75)    25 (21.5--35.25)      30.5 (25.5--38)       0.0092
  V1 vs. V4                                                                             0.0329
  **Sensor 3**                                                                          
  49 (38.25--76.25)   79.5 (57--105.8)      66.5 (53.5--106.5)    89 (65.5--101)        n.s.
  V1 vs. V2                                                                             0.0279
  **Sensor 4**                                                                          
  31 (26.75--48)      48.5 (37.25--58.25)   44 (36--66.75)        54.4 (43.5--67)       0.0523
  V1 vs. V2                                                                             0.0445
  V1 vs. V4                                                                             0.0413
  Sensor 5                                                                              
  12.5 (9--16.8)      19 (13.3--22.5)       15.5 (12.5--25.5)     19.5 (15.8--24.3)     n.s.
  Sensor 6                                                                              
  24 (18.8--33.3)     29.5 (23.3--43.8)     36 (25--41)           32 (24.8--45)         n.s.
  Sensor 7                                                                              
  20.5 (15.3--32)     29 (22.3--38)         29 (25.8--41.3)       32.5 (29--36.8)       n.s.
  Sensor 8                                                                              
  30.5 (20.3--44.5)   42 (32.5--55.3)       30 (27.5--48.3)       41.5 (29.5--49.5)     n.s.

*The behavior of each sensor (sensor 1--sensor 8) is shown. Sensors whose mean values differ across visits are shown in bold*.

*Data, expressed as median and interquartile range, are relative changes in sensor frequency \[(Rmax-R0)/R0\] (Hz). Intra-group, between-visit comparisons were performed with Friedman\'s test. If overall P was lower than 0.05, considered significant, Wilcoxon signed rank test was performed. n.s., not significant; V, visit*.

There was no difference in sensor response using either e-nose when other paired visits were compared (Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}).

Metabolomic analysis of EBC with NMR spectroscopy
-------------------------------------------------

A total of 56 EBC NMR spectra obtained from 14 study subjects across visits were analyzed. Typical EBC ^1^H-NMR spectra obtained from a COPD patient across visits are shown in Figure [S1](#SM8){ref-type="supplementary-material"}. EBC metabolomics with NMR spectroscopy discriminated between fluticasone propionate/salmeterol FDC maintenance treatment (visit 1) and treatment with beclomethasone/formoterol FDC for 4 weeks (visit 4) (accuracy = 72%, *P* = 0.01) (Figure [S2](#SM9){ref-type="supplementary-material"}). Formate levels were higher at visit 1 (694.9 ± 360.5 arbitrary units, median ± median absolute deviation \[MAD\]) than at visit 4 (409.2 ± 224.8 arbitrary units, *P* = 0.029) (Table [6](#T6){ref-type="table"}, Figures [S3A,B](#SM10){ref-type="supplementary-material"}). Other paired comparisons showed accuracy below the significant threshold set at 70% (Table [S1](#SM1){ref-type="supplementary-material"}). After 4-week treatment with beclomethasone/formoterol FDC (visit 4), EBC acetate levels were lower than those measured after 4-week treatment with formoterol alone (visit 3) (*P* = 0.009) (Table [6](#T6){ref-type="table"}). Several EBC metabolites, including formate, phenol, methanol, trimethylamine, acetone, acetoine, acetate, n-butyrate, lactate, 3-hydroxyisovalerate, ethanol, propionate, and leucine-o-butyrate were identified (Figure [3](#F3){ref-type="fig"}). Apart from formate and acetate, their levels were similar across visits (Table [6](#T6){ref-type="table"}).

###### 

Paired comparison of exhaled breath condensate (EBC) metabolite concentrations at each visit using Wilcoxon signed-rank test.

                         **Visit 1**              **Visit 2**              **Visit 3**              **Visit 4**              **Visit 1 vs. visit 2**   **Visit 1 vs. visit 3**   **Visit 1 vs. visit 4**   **Visit 2 vs. visit 3**   **Visit 2 vs. visit 4**   **Visit 3 vs. visit 4**
  ---------------------- ------------------------ ------------------------ ------------------------ ------------------------ ------------------------- ------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  Acetate                7, 322.51 ± 3, 372.29    8, 634.57 ± 6, 598.25    10, 385.09 ± 4, 929.83   4, 683.2 ± 1, 518.54     0.95                      0.33                      0.33                      0.95                      0.12                      0.01
  Acetoine               706.10 ± 482.55          512.18 ± 215.73          730.90 ± 311.39          546.27 ± 360.24          0.12                      0.54                      0.27                      0.09                      0.54                      0.12
  Acetone                6, 152.10 ± 3, 456.11    6, 072.73 ± 1, 730.04    6, 850.06 ± 2, 420.90    6, 579.12 ± 2, 468.53    0.81                      1.00                      0.22                      0.58                      0.63                      0.17
  3-Hydroxyisovalerate   326.31 ± 64.86           351.19 ± 45.66           388.33 ± 44.43           376.95 ± 89.09           0.71                      0.30                      0.58                      0.33                      0.81                      0.33
  Ethanol                488.16 ± 99.84           538.82 ± 201.68          754.17 ± 384.75          544.54 ± 238.66          1.00                      0.06                      0.95                      0.39                      0.95                      0.08
  Formate                694.95 ± 360.47          695.14 ± 519.50          424.52 ± 131.84          409.16 ± 224.76          0.86                      0.67                      0.03                      0.17                      0.05                      0.05
  Lactate                444.24 ± 158.85          284.10 ± 92.29           352.78 ± 142.45          289.46 ± 115.33          0.95                      0.95                      0.12                      0.95                      0.12                      0.30
  Leucine/n-butyrate     1, 431.78 ± 482.18       2, 484.15 ± 1743.00      2, 002.49 ± 896.17       1, 583.98 ± 537.93       0.50                      0.12                      0.67                      0.71                      0.12                      0.06
  Methanol               14, 225.48 ± 7, 044.87   16, 268.66 ± 7, 711.03   11, 570.77 ± 2, 751.26   14, 358.75 ± 8, 341.86   1.00                      0.36                      0.95                      0.81                      0.63                      0.67
  n-butyrate             664.07 ± 198.96          1, 572.65 ± 1, 205.33    1, 099.32 ± 468.94       766.91 ± 251.52          0.22                      0.14                      0.86                      0.71                      0.12                      0.17
  Phenol                 443.05 ± 224.90          325.68 ± 204.11          354.39 ± 158.40          335.79 ± 204.24          0.22                      0.76                      0.36                      0.07                      0.63                      0.39
  Proprionate            1, 542.86 ± 739.74       2, 394.86 ± 1, 967.45    2, 519.65 ± 1, 754.52    988.23 ± 706.23          0.46                      0.12                      0.58                      0.46                      0.46                      0.09
  Trimethylamine         364.99 ± 260.65          343.87 ± 262.45          348.39 ± 210.49          301.78 ± 195.88          0.76                      0.36                      0.86                      0.39                      0.90                      0.46

*Metabolite concentrations are reported as median arbitrary units ± median absolute deviation (MAD)*.

![An example of a typical EBC NMR spectrum at 600 MHz. All metabolites assigned and quantified are reported in figure.](fphar-09-00258-g0003){#F3}

F~E~NO
------

There was no difference in F~E~NO concentrations in patients with COPD across visits (overall *P* = 0.35) (Table [S2](#SM2){ref-type="supplementary-material"}).

Measurement of PGE~2~ and 15-F~2t~-isoprostane in sputum supernatants and EBC
-----------------------------------------------------------------------------

PGE~2~ concentrations were detected in 49 out of a total of 56 sputum supernatant samples. Compared with formoterol alone post-treatment values (visit 3), lower sputum PGE~2~ concentrations were observed after 4-week treatment with beclomethasone/formoterol FDC (visit 4) (*P* = 0.008) and on maintenance treatment with fluticasone propionate/salmeterol FDC (visit 1) (*P* = 0.021) (Table [S3](#SM3){ref-type="supplementary-material"}). These data suggest that treatment with ICS FDC, containing either fluticasone propionate or beclomethasone dipropionate, reduces sputum PGE~2~ concentrations. There was no between-visit differences in EBC PGE~2~ or sputum and EBC 15-F~2t~-isoprostane concentrations (Table [S3](#SM3){ref-type="supplementary-material"}).

Sputum cell analysis
--------------------

Eight patients with COPD had a complete set of sputum slides (visit 1 to visit 4) (Table [S4](#SM4){ref-type="supplementary-material"}). No patient with COPD had sputum eosinophilia, as defined by sputum cell counts \>3%, at visit 1 (screening visit). There was no within-group difference in sputum cell counts (Table [S4](#SM4){ref-type="supplementary-material"}). Percentage sputum cell counts in all valid sputum slides are shown in Table [S5](#SM5){ref-type="supplementary-material"}.

Correlations
------------

Responses within each individual e-nose and between e-noses were correlated, whereas EBC metabolites detected by NMR spectroscopy were not correlated with either e-noses, except EBC phenol which was correlated with 16 carbon polymer sensors (Figure [4](#F4){ref-type="fig"}). In EBC, there was a correlation between PGE~2~ and formate (*r* = 0.78, *P* = 5.06·10^−11^), acetone (*r* = 0.63, *P* = 1.64·10^−6^), lactate (*r* = 0.64, *P* = 6.03·10^−7^), n-butyrate (*r* = 0.82, *P* = 5.89·10^−13^), propionate (*r* = 0.59, *P* = 8.26·10^−6^), and acetate (*r* = 0.71, *P* = 1.23·10^−8^) (Figure [4](#F4){ref-type="fig"}).

![Heatmap showing correlations between study outcome measures in 14 patients with COPD at visit 1 to visit 4 (*n* = 56). R values are shown as different degree of color intensity (red, positive correlations; blue, negative correlation).](fphar-09-00258-g0004){#F4}

Quartz crystal sensor 4 (*r* = −0.35, *P* = 0.023) and 7 (*r* = −0.31, *P* = 0.041) negatively correlated with sputum neutrophils. These showed negative correlation with FEV~1~/FVC (*r* = −0.34; *P* = 0.028) (Figure [4](#F4){ref-type="fig"}).

Multidimensional integrated model for assessment of pharmacological treatment
-----------------------------------------------------------------------------

In the 14 COPD study participants, multidimensional pairwise discrimination models were built. The models discriminated between maintenance treatment with fluticasone propionate/salmeterol (visit 1) vs. 4-week treatment with formoterol alone (visit 3) (accuracy = 71.5%, *P* \< 0.01); the univariate analysis showed differences in sputum supernatant PGE~2~ and FEV~1~/FVC ratio (Table [7](#T7){ref-type="table"}); between maintenance treatment with fluticasone propionate/salmeterol (visit 1) vs. 4-week treatment with beclomethasone/formoterol (visit 4) (accuracy = 82.5%, *P* \< 0.01); the univariate analysis showed differences in EBC formate and e-noses (Table [7](#T7){ref-type="table"}); between 4-week treatment with formoterol alone (visit 3) vs. 4-week treatment with beclomethasone/formoterol (visit 4) (accuracy = 74.6%, *P* \< 0.01); the univariate analysis showed differences in sputum PGE~2~ and EBC acetate (Table [7](#T7){ref-type="table"}).

###### 

Classification accuracies with 95% confidence interval and P values among different pharmacological treatments from visit 1 to visit 4 based on multidimensional PLS models in 14 patients with COPD.

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  **Comparison**        **Overall accuracy (*P*-value)**   **Model quality**   **Variable**                   ***P*-value**                   
  --------------------- ---------------------------------- ------------------- ------------------------------ ------------------------------- -------
  Visit 1 vs. Visit 2   66.4%\                             AUC 0.714\          Carbon polymer sensor e-nose   Sensor2                         0.036
                        (CI 95% 66.0--66.9%)\              Youden\'s J 0.294                                                                  
                        (*P* = 0.12)                                                                                                          

                                                                                                              Sensor8                         0.021

                                                                                                              Sensor19                        0.032

                                                                                                              Sensor21                        0.031

                                                                                                              Sensor24                        0.040

                                                                                                              Sensor25                        0.049

                                                                                                              Sensor27                        0.017

                                                                               Quartz crystal sensor e-nose   Sensor 3                        0.028

                                                                                                              Sensor 4                        0.044

                                                                               Spirometry                     PEF, % pred                     0.033

                                                                                                              PEF, L                          0.044

  Visit 1 vs. Visit 3   71.5%\                             AUC 0.704\          Eicosanoids                    PGE~2~ in sputum supernatants   0.021
                        (CI 95% 71.1--72.0%)\              Youden\'s J 0.446                                                                  
                        (*P* \< 0.01)                                                                                                         

                                                                               Spirometry                     FEV~1~/FVC, %                   0.008

  Visit 1 vs. Visit 4   82.5%\                             AUC 0.857\          NMR spectroscopy               Formate in EBC                  0.029
                        (CI 95% 82.0--83.0%)\              Youden\'s J 0.666                                                                  
                        (*P* \< 0.01)                                                                                                         

                                                                               Carbon polymer sensor e-nose   Sensor1                         0.006

                                                                                                              Sensor2                         0.005

                                                                                                              Sensor4                         0.004

                                                                                                              Sensor7                         0.005

                                                                                                              Sensor8                         0.006

                                                                                                              Sensor12                        0.005

                                                                                                              Sensor14                        0.005

                                                                                                              Sensor15                        0.007

                                                                                                              Sensor16                        0.009

                                                                                                              Sensor19                        0.005

                                                                                                              Sensor21                        0.006

                                                                                                              Sensor24                        0.003

                                                                                                              Sensor25                        0.005

                                                                                                              Sensor27                        0.001

                                                                                                              Sensor32                        0.007

                                                                               Quartz crystal sensor e-nose   Sensor 2                        0.032

                                                                                                              Sensor 4                        0.041

  Visit 2 vs. Visit 3   59.9%\                             AUC 0.571\          Spirometry                     FEF~25−75%~, L                  0.029
                        (CI 95% 58.8--61.1%)\              Youden\'s J 0.134                                                                  
                        (*P* = 0.23)                                                                                                          

                                                                                                              FEF~25−75%~, % pred             0.026

  Visit 2 vs. Visit 4   59.8%\                             AUC 0.556\          Carbon polymer sensor e-nose   Sensor 24                       0.037
                        (CI 95% 58.2--61.3%)\              Youden\'s J 0.214                                                                  
                        (*P* = 0.12)                                                                                                          

  Visit 3 vs. Visit 4   74.6%\                             AUC 0.760\          Eicosanoids                    PGE~2~ in sputum supernatants   0.008
                        (CI 95% 73.9--75.2%)\              Youden\'s J 0.454                                                                  
                        (*P* \< 0.01)                                                                                                         

                                                                               NMR spectroscopy               Acetate in EBC                  0.009
  ---------------------------------------------------------------------------------------------------------------------------------------------------

*The significant variables in the univariate analysis of each experimental technique are also reported (Wilcoxon signed rank test P-values). AUC, area under the curve; EBC, exhaled breath condensate; FEF~25−75%~, forced expiratory flow at 25--75% of the forced vital capacity; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; NMR, nuclear magnetic resonance; PEF, peak expiratory flow; PGE~2~, prostaglandin E~2~; % pred, percentage of predicted value; PLS, partial least squares*.

The multidimensional models showed higher accuracy than the models based on spirometry alone (Table [8](#T8){ref-type="table"}). PLS score plots are centrosymmetric given the pairwise nature of the analyses performed which leads to a matrix with a two block structure with opposite signs, thus producing symmetric PLS scores. This explains the same values of sensitivity and specificity. During cross-validation, when a multilevel PLS model is built from the training set, the entire variation splitting procedure is performed (van Velzen et al., [@B36]; Westerhuis et al., [@B39]). The procedure should, therefore, be adapted to keep the paired data structure both in the training and in the test set. As a result, complete individuals are left out of the training set (per individual validation, not per sample). At each step, if a sample of one individual is mistaken, inevitably the other is mistaken in the opposite way, leading to a fully symmetric confusion matrix. Of course, this symmetry is broken when considering more than just two time points. Further information on results is provided in the online Supplementary Material (Presentation [1](#SM6){ref-type="supplementary-material"}).

###### 

Comparison between a multidimensional integrated model including breathomics and a model based on spirometry alone used for assessing the effects of pharmacological treatment in 14 patients with COPD.

  **Comparison**        **Spirometry-based model**   **Multidimensional integrated model**                                                               
  --------------------- ---------------------------- --------------------------------------- ------ ------- ------- ------- ------------- ------ ------- -------
  Visit 1 vs. Visit 2   0.689                        *P* = 0.06                              3.45   0.650   0.650   0.714   *P* = 0.12    3.90   0.664   0.664
  Visit 1 vs. Visit 3   0.704                        *P* = 0.07                              3.54   0.653   0.653   0.704   *P* \< 0.01   6.29   0.715   0.715
  Visit 1 vs. Visit 4   0.561                        *P* = 0.90                              0.34   0.367   0.367   0.857   *P* \< 0.01   22.2   0.825   0.825
  Visit 2 vs. Visit 3   0.729                        *P* = 0.03                              6.36   0.716   0.716   0.571   *P* = 0.23    2.23   0.599   0.599
  Visit 2 vs. Visit 4   0.648                        *P* = 0.43                              0.85   0.480   0.480   0.556   *P* = 0.12    2.21   0.598   0.598
  Visit 3 vs. Visit 4   0.658                        *P* = 0.11                              3.16   0.640   0.640   0.760   *P* \< 0.01   8.63   0.746   0.746

*AUC, area under the curve; OR, odds ratio*.

*P-values have been obtained through 100-fold permutation tests and are referred to the AUC values*.

Discussion {#s4}
==========

The principal messages of the present study are: (1) breathomics can be successfully applied to assessment of effects of corticosteroid treatment and withdrawal with ICS/LABA in patients with COPD; (2) breathomics results are confirmed by the concordance of three different breathomics techniques (carbon polymer sensor e-nose, quartz crystal sensor e-nose, NMR-based metabolomics) applied to the gaseous and aerosol particle (EBC) phase of the exhaled breath. These techniques provide complementary information; (3) a multidimensional, integrated, model including breathomics, improves the ability of identifying pharmacological treatment-induced effects compared with a monodimensional model based on standard pulmonary function testing; (4) this approach provides insights into the anti-inflammatory effects of ICS in patients with COPD as reflected by reduced sputum PGE~2~ and EBC acetate concentrations after beclomethasone/formoterol FDC vs. formoterol alone.

In a breathomics multidimensional approach to assessment of drugs for COPD, we show anti-inflammatory effects of an extrafine beclomethasone/formoterol FDC pMDI vs. formoterol alone as reflected by reduced levels of sputum PGE~2~, a potent inflammatory mediator in the airways (Clarke et al., [@B8]; Holden et al., [@B20]), and EBC acetate which were found elevated in COPD patients (De Laurentiis et al., [@B9], [@B10]; Airoldi et al., [@B1]; Santini et al., [@B34]).

We also show that short-term treatment with an extrafine beclomethasone/formoterol FDC pMDI is associated with different breathprints as compared with regular fluticasone propionate/formoterol FDC DPI in patients with COPD. These results might suggest that various ICS/LABA formulations have different effects on breathomics outcomes, although the biological implications of these findings are unknown and have to be defined.

Treatment with either ICS/LABA FDC vs. inhaled formoterol alone was associated with a slight, but significant, increase in small airway function as reflected by FEF~25−75%~ and FEV~1~/FVC values, whereas higher PEF values were observed after beclomethasone/formoterol (visit 2) than on regular fluticasone propionate/salmeterol (visit 1), suggesting that treatment-induced e-nose breathprint variations parallel the observed functional changes only to a limited extent. Interestingly, functional effects were observed after only 4-week treatment with inhaled beclomethasone/formoterol, a relatively short duration of treatment for COPD trials, and in patients with COPD who had normal sputum eosinophils, negative reversibility test to bronchodilators, negative skin prick tests, and no history of atopy, thus, excluding an asthma component, on which ICS are generally more effective.

The strong correlation between most sensors within each individual e-nose indicates a high degree of sensor redundancy, whereas a similar behavior of e-nose based on different technologies confirms the results of the exhaled breath analysis. Of note, quartz crystal sensors, but not carbon polymer sensors, showed correlation with sputum neutrophils. On the other hand, the lack of correlation between EBC metabolites detected by NMR spectroscopy and either e-noses suggests that a comprehensive breathomics approach might be complementary and increase the level of information. In EBC, there was a correlation between PGE~2~, an eicosanoid which can have potent pro-inflammatory effects in the airways, and formate (*r* = 0.78), acetone (*r* = 0.63), lactate (*r* = 0.64), n-butyrate (*r* = 0.82), propionate (*r* = 0.59), and acetate (*r* = 0.71) suggesting that these EBC metabolites might reflect respiratory inflammation. These correlations are unlikely to be explained by individual variability in aerosol particle formation (Effros et al., [@B13]) as there was no correlation between EBC 15-F~2t~-isoprostane and EBC metabolites nor between EBC PGE~2~ and EBC 15-F~2t~-isoprostane. For discussion on correlations see also online Supplemenatry Material (Presentation [1](#SM6){ref-type="supplementary-material"}).

Unlike a standard efficacy model based on spirometry, the multidimensional model used in our study was able to distinguish between pharmacological treatments (accuracy \> 70%) in 3 out of 6 possible paired comparisons. This might increase the chance of detecting drug effects in COPD patients. In line with an anti-inflammatory effect of ICS, sputum concentrations of PGE~2~, the key between-treatment discriminating outcome measure, were lower after treatment with either ICS/LABA FDC compared with formoterol alone. By contrast, other inflammatory outcomes, including sputum neutrophil cell counts, EBC PGE~2~, and sputum and EBC 15-F~2t~-isoprostane, showed steroid resistance.

Most of the EBC metabolites derive from pyruvate (Airoldi et al., [@B1]). Many breath volatile and non-volatile compounds are product of bacterial metabolism (Airoldi et al., [@B1]). Moreover, breathomics techniques, including e-noses and NMR spectroscopy, can be used for detecting and identifying bacterial species (Lim et al., [@B23]; Palama et al., [@B30]). For these reasons, exhaled breath analysis has been proposed as a powerful tool to identify bacterial metabolomic signatures (Airoldi et al., [@B1]). However, our approach is not suitable for identifying the cellular source(s) of EBC metabolites for which *in vitro* studies are required.

Elevated EBC formate and acetate levels have been reported in COPD patients compared with healthy subjects (De Laurentiis et al., [@B9], [@B10]). These findings have been confirmed in a recent ^1^H-NMR spectroscopy study showing that EBC acetate is 36-fold higher and EBC formate is 2.5 higher in patients with emphysema due to α~1~-antitrypsin deficiency than in healthy subjects. Interestingly, we found reduced EBC levels of acetate and formate after 4-week beclomethasone/formoterol treatment. These preliminary findings suggest a potential anti-inflammatory mechanism of ICS involving a change in bacterial metabolism which might have profound implications in how ICS reduce the frequency of COPD exacerbations or increase the risk of pneumonia.

Study strengths rely on the fact that this is the first prospective evidence of the effects of pharmacological treatment and steroid withdrawal on breathomics in COPD patients, the multidimensional, non-invasive, approach to drug assessment requiring a systems medicine-based data analysis, the use of complementary breathomics techniques, and the completeness of data collected. The limited number of study subjects, the open-label, uncontrolled, design of the pharmacological study, the short duration of treatment/withdrawal phases, the lack of training and testing validation and external validation cohorts, represent limitations which preclude definitive conclusions.

In conclusion, breathomics can be used for assessing the effects of treatment and steroid withdrawal with ICS/LABA in patients with COPD. The present pilot, proof-of-concept, study provides a rational basis for large, randomized, controlled, pharmacological trials in patients with COPD using a similar multidimensional approach.
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